Loading…
Loading…
AQB does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for AQB and 80,000+ other tickers.
See exactly how AQB's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for AQB and 80,000+ other tickers.
AquaBounty Technologies, Inc. is a biotechnology firm dedicated to boosting productivity within the commercial fish farming sector across the United States and Canada. The company's research initiatives delve into genetics, genomics, fish health, and nutrition. Its flagship offering is AquAdvantage Salmon, a genetically engineered Atlantic salmon intended for human consumption. Beyond this, AquaBounty also supplies conventional Atlantic salmon, along with salmon eggs, juvenile fish (fry), and various byproducts. Established in 1991, the firm maintains its headquarters in Maynard, Massachusetts. It operated under the name Aqua Bounty Farms, Inc. until its rebranding in June 2004.
Harvard, Massachusetts--(Newsfile Corp. - August 6, 2026) - AquaBounty Technologies, Inc. (NASDAQ: AQB) ("AquaBounty," "we," "our" or the "Company") today announced that it is expanding its ongoing strategic review process for its Pioneer, Ohio property to include opportunities related to power infrastructure and energy development. The Company has previously been engaged in efforts to monetize the Pioneer property through discussions with parties in the aquaculture industry.
AquaBounty Technologies, Inc. (NASDAQ: AQB - Get Free Report) was the target of a significant drop in short interest during the month of January. As of January 30th, there was short interest totaling 17,318 shares, a drop of 25.9% from the January 15th total of 23,366 shares. Approximately 0.5% of the shares of the company are
AquaBounty Technologies (NASDAQ: AQB - Get Free Report) and Tyra Biosciences (NASDAQ: TYRA - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability. Institutional and Insider Ownership 8.9% of AquaBounty
AquaBounty Technologies, Inc. (NASDAQ: AQB - Get Free Report) was the target of a significant decline in short interest in the month of December. As of December 15th, there was short interest totaling 11,813 shares, a decline of 48.8% from the November 30th total of 23,090 shares. Currently, 0.3% of the shares of the stock are
Harvard, Massachusetts--(Newsfile Corp. - October 28, 2025) - AquaBounty Technologies, Inc. (NASDAQ: AQB) ("AquaBounty" or the "Company"), a land-based aquaculture company utilizing technology to enhance productivity and sustainability, today announced the Company's financial results for the third quarter and nine months ended September 30, 2025. Third Quarter 2025 Highlights Net loss for the quarter ended September 30, 2025 was $1.4 million compared to a net loss of $3.4 million for the quarter ended September 30, 2024.